Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Peterson

Family Medicine Sioux City, IA Doctor of Osteopathy

NPI 1326013426 CMS profile 331719

2600 Outer Dr N, Sioux City, IA 51104

Open in the dashboard

General payments

$7,683

537 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Peterson of Sioux City, IA is reported in the CMS Open Payments database as having received $7,683 across 537 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,915 122
2024 General $1,796 117
2023 General $1,150 87
2022 General $1,008 75
2021 General $685 52
2020 General $507 29
2019 General $622 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Peterson
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Paul Peterson were reported at $1,915. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Paul Peterson Family Medicine median Middle half National median
2019 $622 $150 $41–$543 $163
2020 $507 $120 $32–$415 $114
2021 $685 $137 $35–$551 $132
2022 $1,008 $137 $37–$512 $149
2023 $1,150 $149 $42–$545 $160
2024 $1,796 $156 $44–$560 $164
2025 $1,915 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,334 127 payments
  2. AstraZeneca Pharmaceuticals LP $1,007 45 payments
  3. Novo Nordisk Inc $782 58 payments
  4. Pfizer Inc. $686 52 payments
  5. Astellas Pharma US Inc $342 22 payments
  6. AbbVie, Inc. $315 18 payments
  7. Merck Sharp & Dohme Corporation $314 19 payments
  8. Abbott Laboratories $302 17 payments
  9. Lilly USA, LLC $298 28 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $266 16 payments
  11. Other $2,039 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,658 535 payments
  2. Education $25 2 payments
Products named General payments · program years 2019–2025
  1. EVENITY $765 70 payments
  2. Prolia $722 67 payments
  3. Ozempic $616 48 payments
  4. RYBELSUS $562 44 payments
  5. ELIQUIS $504 34 payments
  6. Repatha $502 49 payments
  7. FARXIGA $471 17 payments
  8. Otezla $424 45 payments
  9. Veozah $278 18 payments
  10. GARDASIL 9 $267 16 payments
  11. Other $5,770 399 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 141 drugs

Part D claims

8,551

Median for Family Practice: 1,826

Drug cost

$482,171

Median for Family Practice: $120,094

Branded share of claims

17.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 109 $109,017
Eliquis Apixaban Brand 92 $76,287
Farxiga Dapagliflozin Propanediol Brand 52 $30,829
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 38 $27,968
Tresiba Flextouch U-200 Insulin Degludec Brand 19 $25,004
Januvia Sitagliptin Phosphate Brand 34 $20,157
Myrbetriq Mirabegron Brand 32 $16,006
Breo Ellipta Fluticasone/Vilanterol Brand 32 $15,699
Jardiance Empagliflozin Brand 12 $15,109
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 25 $14,833

The 10 drugs with the highest cost, of 141 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$218,955

Of which drugs: $43,432

Medicare patients

325

Average age 73

Services billed

12,899

191 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 41%
Chronic kidney disease 35%
Diabetes 25%
COPD 22%
Depression 22%
Osteoporosis 17%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 12 1,260 $25,743
Vaccine for influenza for injection into muscle 90662 Office 102 105 $8,348
Pcv20 vaccine im 90677 Office 23 25 $6,964
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 316 $211

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $140
  • E.R. Squibb & Sons, L.L.C. $18
$158 92 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $120
$120 52 —
Veozah
  • Astellas Pharma US Inc $113
$113 — —
MOUNJARO
  • Lilly USA, LLC $100
$100 — —
EVENITY
  • Amgen Inc. $82
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

537 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record